WARNING: This product is for research use only, not for human or veterinary use.
XL-820 is an orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. XL820 binds to and inhibits the receptor tyrosine kinases for vascular endothelial drowth factor (VEGF), c-kit, and platelet-derived growth factor (PDGF). In tumor models of breast carcinomas, gliomas, and leukemia, this agent exhibits dose-dependent growth inhibition and has been shown to cause tumor regression.
Price and Availability
XL-820 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
MedKoo Cat#: 206016
XL820; XL 820; XL-820; XL820001
>98% (or refer to the Certificate of Analysis)
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Soluble in DMSO, not in water
>5 years if stored properly
This drug may be formulated in DMSO
Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
Harmonized System Code: